The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

hours per response:

4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous X None **Names**

Entity Type

Limited Liability Company

0001408443

Name of Issuer

Milestone Pharmaceuticals Inc.

Jurisdiction of **Incorporation/Organization**

CANADA (FEDERAL LEVEL)

X Corporation

Limited Partnership

General Partnership

Business Trust Other (Specify)

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

Milestone Pharmaceuticals Inc.

Street Address 1 Street Address 2

1111 DR. FREDERIK-PHILIPS BLVD. SUITE 420

> ZIP/PostalCode **Phone Number of Issuer** City **State/Province/Country**

MONTREAL QUEBEC, CANADA H4M 2X6 (514) 336-0444

3. Related Persons

Last Name First Name Middle Name

State/Province/Country

Douville **Philippe**

> **Street Address 1** Street Address 2

1111 DR. FREDERIK-PHILIPS **SUITE 420** BLVD.

City

ZIP/PostalCode

Montreal QUEBEC, CANADA H4M 2X6

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Liebert Debra

> **Street Address 1 Street Address 2**

1111 DR. FREDERIK-PHILIPS **SUITE 420**

BLVD.

ZIP/PostalCode City State/Province/Country

Montreal QUEBEC, CANADA H4M 2X6

Relationship: Executive Officer X Director Promoter

Last Name First Name Middle Name

Plat Francis

Street Address 1 Street Address 2

1111 DR. FREDERIK-PHILIPS

BLVD.

City State/Province/Country ZIP/PostalCode

Montreal QUEBEC, CANADA H4M 2X6

SUITE 420

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Maguire Martin

Street Address 1 Street Address 2

1111 DR. FREDERIK-PHILIPS

BLVD.

SUITE 420

City State/Province/Country ZIP/PostalCode

Montreal QUEBEC, CANADA H4M 2X6

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Wight Douglas

Street Address 1 Street Address 2

1111 DR. FREDERIK-PHILIPS

BLVD.

City State/Province/Country ZIP/PostalCode

Montreal QUEBEC, CANADA H4M 2X6

SUITE 420

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Truex Paul

Street Address 1 Street Address 2

1111 DR. FREDERIK-PHILIPS

BLVD.

SUITE 420

City State/Province/Country ZIP/PostalCode

Montreal QUEBEC, CANADA H4M 2X6

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Rosconi Yves

Street Address 1 Street Address 2

1111 DR. FREDERIK-PHILIPS

BLVD.

SUITE 420

City State/Province/Country ZIP/PostalCode

Montreal QUEBEC, CANADA H4M 2X6

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Borenstein Ela

Street Address 1 Street Address 2

1111 DR. FREDERIK-PHILIPS

BLVD.

City State/Province/Country ZIP/PostalCode

Montreal QUEBEC, CANADA H4M 2X6

SUITE 420

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Weiner Scott

Street Address 1 Street Address 2

1111 DR. FREDERIK-PHILIPS SUITE 420

BLVD.

City State/Province/Country ZIP/PostalCode

Montreal QUEBEC, CANADA H4M 2X6

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Cowen Benjamin

Street Address 1 Street Address 2

1111 DR. FREDERIK-PHILIPS

BLVD.

SUITE 420

City State/Province/Country ZIP/PostalCode

Montreal QUEBEC, CANADA H4M 2X6

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Beauregard Nathalie

Street Address 1 Street Address 2

1111 DR. FREDERIK-PHILIPS

BLVD.

SUITE 420

City State/Province/Country ZIP/PostalCode

Montreal QUEBEC, CANADA H4M 2X6

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Health Care Retailing
Banking & Financial Services Biotechnology

Commercial Banking Health Insurance Technology
Insurance Hospitals & Physicians Computers

Investing

Investment Banking

X Pharmaceuticals

Telecommunications

Pooled Investment Fund

Other Health Care

Other Technology

Is the issuer registered as Manufacturing Travel

an investment company under the Investment Company

Real Estate Airlines & Airports

Act of 1940? Commercial Lodging & Conventions

Construction Yes No Tourism & Travel Services Other Banking & Financial Services **REITS & Finance** Other Travel **Business Services** Residential Other Energy Other Real Estate Coal Mining **Electric Utilities Energy Conservation Environmental Services** Oil & Gas

5. Issuer Size

Other Energy

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company	Investment Company Act Section 3(c)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)		
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)		
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	Section 3(c)(3)	Section 3(c)(11)		
Rule 505	Section 3(c)(4)	Section 3(c)(12)		
X Rule 506(b)	Section 3(c)(5)	Section 3(c)(13)		
Rule 506(c)	Section 3(c)(6)	Section 3(c)(14)		
Securities Act Section 4(a)(5)	Section 3(c)(7)			

7. Type of Filing

X New Notice Date of First Sale 2015-06-03 First Sale Yet to Occur Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Other (describe)

Is this offering being made in connection with a business combination transaction, such as Yes X No a merger, acquisition or exchange offer? Clarification of Response (if Necessary): 11. Minimum Investment Minimum investment accepted from any outside investor \$0 USD 12. Sales Compensation Recipient Recipient CRD Number X None (Associated) Broker or Dealer CRD X None (Associated) Broker or Dealer X None Number **Street Address 1 Street Address 2** ZIP/Postal City State/Province/Country Code State(s) of Solicitation (select all that apply) All Check "All Statesâ€∏ or check individual Foreign/non-US States States 13. Offering and Sales Amounts **Total Offering Amount** \$9,406,593 USD or Indefinite Total Amount Sold \$3,848,369 USD Total Remaining to be Sold \$5,558,224 USD or Indefinite Clarification of Response (if Necessary): 14. Investors Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 15. Sales Commissions & Finder's Fees Expenses Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not

known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD **Estimate** Finders' Fees \$0 USD **Estimate**

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

> \$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Milestone Pharmaceuticals Inc.	/s/ Philippe Douville	Philippe Douville	Chief Executive Officer	2015-06-12

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.